Phase I, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Dose-Escalation Study of a Single Intravenous Administration of MDX-1106, a Fully Human Monoclonal Antibody to PD-1, in Subjects With Active Hepatitis C Genotype 1 Infection

Trial Profile

Phase I, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Dose-Escalation Study of a Single Intravenous Administration of MDX-1106, a Fully Human Monoclonal Antibody to PD-1, in Subjects With Active Hepatitis C Genotype 1 Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2009

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Bristol-Myers Squibb; Medarex
  • Most Recent Events

    • 28 Oct 2009 Actual end date (1 Oct 2009) added as reported by ClinicalTriasl.gov
    • 28 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 31 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top